Elevance Health, Inc. (NYSE:ELV) Shares Bought by Bedel Financial Consulting Inc.

Bedel Financial Consulting Inc. increased its holdings in Elevance Health, Inc. (NYSE:ELV) by 26.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,596 shares of the company’s stock after buying an additional 334 shares during the quarter. Bedel Financial Consulting Inc.’s holdings in Elevance Health were worth $642,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ELV. Marathon Asset Management Ltd acquired a new position in Elevance Health during the fourth quarter worth $83,781,000. Kelly Financial Group LLC acquired a new position in shares of Elevance Health during the fourth quarter valued at approximately $382,000. Mission Wealth Management LP raised its holdings in shares of Elevance Health by 47.9% during the fourth quarter. Mission Wealth Management LP now owns 3,138 shares of the company’s stock valued at $1,158,000 after acquiring an additional 1,017 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of Elevance Health during the fourth quarter worth $921,000. Finally, Jones Financial Companies Lllp raised its position in shares of Elevance Health by 120.0% in the fourth quarter. Jones Financial Companies Lllp now owns 14,028 shares of the company’s stock valued at $5,175,000 after buying an additional 7,653 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Down 0.3 %

Shares of NYSE ELV opened at $395.63 on Tuesday. The business has a 50-day moving average of $388.27 and a two-hundred day moving average of $437.33. The company has a market capitalization of $89.95 billion, a price-to-earnings ratio of 15.45, a price-to-earnings-growth ratio of 1.18 and a beta of 0.83. Elevance Health, Inc. has a 1 year low of $362.21 and a 1 year high of $567.26. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Thursday, January 23rd. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.80 by $0.04. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. On average, analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 25th. Shareholders of record on Monday, March 10th will be paid a $1.71 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $6.84 dividend on an annualized basis and a yield of 1.73%. This is a boost from Elevance Health’s previous quarterly dividend of $1.63. Elevance Health’s payout ratio is currently 26.71%.

Analyst Ratings Changes

ELV has been the subject of a number of analyst reports. StockNews.com upgraded Elevance Health from a “hold” rating to a “buy” rating in a research report on Saturday. Mizuho dropped their price objective on shares of Elevance Health from $585.00 to $505.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. Barclays increased their price target on shares of Elevance Health from $501.00 to $512.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Stephens lowered Elevance Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $520.00 to $440.00 in a research report on Wednesday, January 22nd. Finally, Wells Fargo & Company lowered their price target on Elevance Health from $483.00 to $478.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $517.03.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.